Nanion コーポレートブログ


29.08.2019: Pushing the boundaries of hiPSC-CMs in cardiac safety

The new FLEXcyte 96 system for in vitro cardiac contractility measurements is addressing the demands for both physiological relevance and throughput.

We are proud to announce that the platform will be available as of September 16th, 2019!

Read the Whitepaper and learn about iPSC-CM maturity, reference compound effects and where the FLEXcyte 96 technology can be positioned in your drug discovery project.

For FLEXcyte 96 screening services kindly visit innoVitro's official website, for orders, updates and more information on the system please see


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.